Top

Current Dermatology Reports

Published in:

01-12-2018 | Hospital- based Dermatology (D Kroshinsky, Section Editor)

Erythroderma and Figurate Erythemas

Authors: Emily Coleman, Lauren L. Levy

Published in: Current Dermatology Reports | Issue 4/2018

Abstract

Purpose of Review

Erythroderma and figurate erythemas are common reasons for inpatient dermatologic consultation. This review provides an overview of the frequent causes of erythroderma and figurate erythemas in adults and children as well as highlights recent advances in our understanding of the pathomechanisms of these entities.

Recent Findings

With the advent of immunotherapy for the treatment of cancer, there are new medications that may result in drug-induced erythroderma. Additionally, the pathophysiology and immunologic milieu of erythroderma in psoriasis and cutaneous lymphoma has been investigated. More recent biologic agents may be used to treat erythroderma.

Summary

The differential diagnosis of erythroderma and figurate erythemas is broad and often related to underlying systemic diseases. Workup and treatment should focus on identifying and treating an underlying cause when applicable.

Rothe MJ, Bernstein ML, Grant-Kels JM. Life-threatening erythroderma: diagnosing and treating the “red man”. Clin Dermatol. 2005;23:206–17. https://doi.org/10.1016/j.clindermatol.2004.06.018.CrossRefPubMed

• Mistry N, Gupta A, Alavi A, Sibbald RG. A review of the diagnosis and management of erythroderma (generalized red skin). Adv Skin Wound Care. 2015;28:228–36. https://doi.org/10.1097/01.ASW.0000463573.40637.73 Provides helpful guidelines for the physical examination in erythrodermic patients. CrossRefPubMed

Grant-Kels JM, Fedeles F, Rothe MJ. Exfoliative dermatitis. Fitzpatrick’s Dermatology Gen. Med. 8th ed., 2012.

Jack A, Spence A, Nichols B, Chong S, Willians D, Swadron S, et al. Cutaneous conditions leading to dermatology consultation in the emergency department. West J Emerg Med. 2011;12:551–5. https://doi.org/10.5811/westjem.2010.4.1653.CrossRef

Mancusi S, Festa Neto C. Inpatient dermatological consultations in a university hospital. Clinics (Sao Paulo). 2010;65:851–5.CrossRef

Li J, Zheng H-Y. Erythroderma: a clinical and prognostic study. Dermatology. 2012;225:154–62. https://doi.org/10.1159/000342365.CrossRefPubMed

• Whittaker S. Erythroderma. In: Bolognia JL, Schaffer JV, Cerroni L, editors. Dermatology. 4th ed. New York: Elsevier; 2017. Provides a list of drugs associated with erythroderma.

•• Kumar S, Mahajan B, Kaur S, Banipal RS, Singh A. Imatinib mesylate induced erythroderma: a rare case series. J Cancer Res Ther. 2015;11:993. https://doi.org/10.4103/0973-1482.157341 Part of a growing literature indicating imatinib as a cause of erythroderma. CrossRefPubMed

Verma R, Vasudevan B, Pragasam V, Neema S. A rare case of imatinib-induced erythroderma. Indian J Pharmacol. 2013;45:634–5. https://doi.org/10.4103/0253-7613.121386.CrossRefPubMedPubMedCentral

10.

Sanghavi S, Khopkar U, Dongre A. Imatinib mesylate induced erythroderma. Indian J Dermatol Venereol Leprol. 2012;78:408. https://doi.org/10.4103/0378-6323.95491.CrossRefPubMed

11.

Tan GFL, Kong YL, Tan ASL, Tey HL. Causes and features of erythroderma. Ann Acad Med Singap. 2014;43:391–4.PubMed

12.

•• Moy AP, Murali M, Kroshinsky D, Duncan LM, Nazarian RM. Immunologic overlap of helper T-cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis. JAMA Dermatol. 2015;151:753. https://doi.org/10.1001/jamadermatol.2015.2 This article advances our understanding of the shared immunohistochemical profile of erythrodermic psoriasis and atopic dermatitis. While there was a shift towards Th1 response in chronic psoriasis compared to atopic dermatitis, that difference was not observed in the erythrodermic variants of these conditions. CrossRefPubMed

13.

Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol. 1989;21:985–91.CrossRef

14.

Hawilo A, Zaraa I, Benmously R, Mebazaa A, El Euch D, Mokni M, et al. Erythrodermic psoriasis: epidemiological clinical and therapeutic features about 60 cases. Tunis Med. 2011;89:841–7.PubMed

15.

Zhang P, Chen H, Duan Y, Wang W, Zhang T, Li J, et al. Analysis of Th1/Th2 response pattern for erythrodermic psoriasis. J Huazhong Univ Sci Technol Med Sci. 2014;34:596–601. https://doi.org/10.1007/s11596-014-1322-0.CrossRefPubMed

16.

Li L-F, Sujan SA, Yang H, Wang W-H. Serum immunoglobulins in psoriatic erythroderma. Clin Exp Dermatol. 2005;30:125–7. https://doi.org/10.1111/j.1365-2230.2004.01717.x.CrossRefPubMed

17.

•• Lee HH, Patel KR, Singam V, Rastogi S, Silverberg JI. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2018. https://doi.org/10.1016/j.jaad.2018.05.1241. Provides an overview of literature on adult-onset atopic dermatitis, an increasingly recognized clinical entity.

18.

•• Salamon P, Shefler I, Moshkovits I, Munitz A, Horwitz Klotzman D, Mekori YA, et al. IL-33 and IgE stimulate mast cell production of IL-2 and regulatory T cell expansion in allergic dermatitis. Clin Exp Allergy. 2017;47:1409–16. https://doi.org/10.1111/cea.13027 Building off recent evidence that mast cells suppress chronic allergic dermatitis in mice via mast cell-derived IL-2, this article demonstrates that IL-33 and IgE play critical roles in the production of mast cells and IL-2 in vitro. IL-2 led to expansion of Tregs in vitro. CrossRefPubMed

19.

Leclerc-Mercier S, Bodemer C, Bourdon-Lanoy E, Larousserie F, Hovnanian A, Brousse N, et al. Early skin biopsy is helpful for the diagnosis and management of neonatal and infantile erythrodermas. J Cutan Pathol. 2010;37:249–55. https://doi.org/10.1111/j.1600-0560.2009.01344.x.CrossRef

20.

• Moriarty B, Whittaker S. Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma. Expert Rev Hematol. 2015;8:159–71. https://doi.org/10.1586/17474086.2015.984681 Outlines the poor prognosis of erythrodermic CTCL, with average life expectancy of roughly 2 years. CrossRefPubMed

21.

Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2008;159:105–12. https://doi.org/10.1111/j.1365-2133.2008.08612.x.CrossRefPubMed

22.

•• Lewis DJ, Holder BB, Duvic M. The “Duvic regimen” for erythrodermic flares secondary to Staphylococcus aureus in mycosis fungoides and Sézary syndrome. Int J Dermatol. 2018;57:123–4. https://doi.org/10.1111/ijd.13832 Introduces a novel method for treatment of eryhrodermic CTCL flares brought on by S. aureus . CrossRefPubMed

23.

Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Ca. Blood. 2007;110:1713–22. https://doi.org/10.1182/blood-2007-03-055749.CrossRef

24.

Sigurdsson V, Toonstra J, van Vloten WA. Idiopathic erythroderma: a follow-up study of 28 patients. Dermatology. 1997;194:98–101. https://doi.org/10.1159/000246074.CrossRefPubMed

25.

•• King B, Lee AI, Choi J. Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib. J Invest Dermatol. 2017;137:951–4. https://doi.org/10.1016/j.jid.2016.10.044 Provides evidence that hyperosinopihlic syndrome may be successfully treated with JAK inhibition, likely owing to the role of JAK-STAT signaling and gain of function mutation in STAT3 in the pathogenesis of hypereosinophilic syndromes. CrossRefPubMed

26.

•• Miyamoto D, Sotto MN, Otani CSV, Fukumori LMI, Pereira NV, Santi CG, et al. Increased serum levels of vascular endothelial growth factor in pemphigus foliaceus patients with erythroderma. J Eur Acad Dermatol Venereol. 2017;31:333–6. https://doi.org/10.1111/jdv.13905 Provides evidence that the pathogenesis of erythrodermic pemphigus foliaceus may be related to increased levels of VEGF, suggesting that pro-angiogenic factors may be invovled in the etiology of erythrodermic pemphigus foliaceus. CrossRefPubMed

27.

Korman NJ, Woods SG. Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoid. Br J Dermatol. 1995;133:967–71.CrossRef

28.

Amato L, Gallerani I, Mei S, Pestelli E, Caproni M, Fabbri P. Erythrodermic bullous pemphigoid. Int J Dermatol. 2001;40:343–6.CrossRef

29.

Si X, Ge L, Xin H, Cao W, Sun X, Li W. Erythrodermic psoriasis with bullous pemphigoid: combination treatment with methotrexate and compound glycyrrhizin. Diagn Pathol. 2014;9:102. https://doi.org/10.1186/1746-1596-9-102.CrossRefPubMedPubMedCentral

30.

Ko CJ, Milstone LM, Choi J, McNiff JM. Pityriasis rubra pilaris: the clinical context of acantholysis and other histologic features. Int J Dermatol. 2011;50:1480–5. https://doi.org/10.1111/j.1365-4632.2011.04990.x.CrossRefPubMed

31.

Pai VV, Naveen K, Athanikar S, Dinesh U, Reshme P, Divyashree R. Subacute cutaneous lupus erythematosus presenting as erythroderma. Indian J Dermatol. 2014;59:634. https://doi.org/10.4103/0019-5154.143589.CrossRefPubMedPubMedCentral

32.

• Lee W-K, Kim G-W, Cho H-H, Kim W-J, Mun J-H, Song M, et al. Erythrodermic psoriasis treated with golimumab: a case report. Ann Dermatol. 2015;27:446–9. https://doi.org/10.5021/ad.2015.27.4.446 Provides evidence for a new anti-TNF immunologic agent in the treatment of erythrodermic psoriasis. CrossRefPubMedPubMedCentral

33.

•• Kirchhof MG, Wong A, Dutz JP. Cyclosporine treatment of drug-induced hypersensitivity syndrome. JAMA Dermatol. 2016;152:1254–7. https://doi.org/10.1001/jamadermatol.2016.2220 Provides evidence of the efficacy of 3–7-day courses of cyclosporine in DIHS. Demonstrates that cyclosporine is a shorter yet effective alternative to corticosteroid courses. CrossRefPubMed

34.

Macbeth AE, Johnston GA. Twenty-one years of oral retinoid therapy in siblings with nonbullous ichthyosiform erythroderma. Clin Exp Dermatol. 2008;33:190–1. https://doi.org/10.1111/j.1365-2230.2007.02531.x.CrossRefPubMed

35.

Zuberbier T, Iffländer J, Semmler C, Henz BM. Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol. 1996;76:295–7.PubMed

36.

Caffarelli C, Cuomo B, Cardinale F, Barberi S, Dascola C, Agostinis F, et al. Aetiological factors associated with chronic urticaria in children: a systematic review. Acta Derm Venereol. 2013;93:268–72. https://doi.org/10.2340/00015555-1511.CrossRef

37.

•• Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72:519–33. https://doi.org/10.1111/all.13083 Outlines the multifactorial mechanisms that make omalizumab an effective treatment of chronic spontaneous urticaria, including decreasing mast cell releasability, improving the function of basophil IgE receptors, decreasing IgE autoantibody activity, and reversing basopenia. CrossRefPubMedPubMedCentral

38.

Sussman G, Hébert J, Barron C, Bian J, Caron-Guay R-M, Laflamme S, et al. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol. 2014;112:170–4. https://doi.org/10.1016/j.anai.2013.12.005.CrossRef

39.

Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatology. 2014;150:288–90. https://doi.org/10.1001/jamadermatol.2013.8705.CrossRefPubMed

40.

Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci. 2014;73:57–62. https://doi.org/10.1016/j.jdermsci.2013.08.011.CrossRefPubMed

41.

• Labrador-Horrillo M, Ferrer M. Profile of omalizumab in the treatment of chronic spontaneous urticaria. Drug Des Devel Ther. 2015;9:4909. https://doi.org/10.2147/DDDT.S56004 Provides an overview of the pathogenesis, qualityof life impact, and treatment modalities of chronic spontaneous urticaria and outlines the use of omalizumab as an effective new agent for treating chronic spontaneous urticaria. CrossRefPubMedPubMedCentral

42.

Shah KN, Honig PJ, Yan AC. Urticaria multiforme: a case series and review of acute annular urticarial hypersensitivity syndromes in children. Pediatrics. 2007;119:e1177–83. https://doi.org/10.1542/peds.2006-1553.CrossRefPubMed

43.

Emer JJ, Bernardo SG, Kovalerchik O, Ahmad M. Urticaria multiforme. J Clin Aesthet Dermatol. 2013;6:34–9.PubMedPubMedCentral

44.

•• Jachiet M, Flageul B, Deroux A, Le Quellec A, Maurier F, Cordoliani F, et al. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French Nationwide Study of fifty-seven patients. Arthritis Rheumatol. 2015;67:527–34. https://doi.org/10.1002/art.38956 Demonstrates the extensive extracutaneous involvement of hypocomplementic urticarial vasculitis. CrossRefPubMed

45.

• Sharma S, Biswal N. Erythema marginatum. Indian Pediatr. 2015;52:1100 Provides data that indicates that erythema marginatum occurs in less than 10% of cases of acute rheumatic fever. CrossRef

46.

• Saito M, Hatakeyama S. Acute rheumatic fever with erythema marginatum. N Engl J Med. 2016;375:2480–0. https://doi.org/10.1056/NEJMicm1601782 Provides a classic photographic illustration of erythema marginatum. CrossRef

47.

Asbrink E, Hovmark A. Comments on the course and classification of Lyme borreliosis. Scand J Infect Dis Suppl. 1991;77:41–3.PubMed

48.

Shapiro ED. Clinical practice. Lyme disease. N Engl J Med. 2014;370:1724–31. https://doi.org/10.1056/NEJMcp1314325.CrossRefPubMedPubMedCentral

49.

Mullegger RR. Dermatological manifestations of Lyme borreliosis. Eur J Dermatol. 2004;14:296–309.PubMed

50.

• Data and Statistics | Lyme disease | CDC n.d. https://www.cdc.gov/lyme/stats/index.html. Accessed 29 July 2018. Illustrates that the majority of Lyme disease are mostly confined to the northeastern USA with some cases in the midwest and West coast.

51.

•• Stupica D, Lusa L, Maraspin V, Bogovič P, Vidmar D, O’Rourke M, et al. Correlation of culture positivity, PCR positivity, and burden of Borrelia burgdorferi sensu lato in skin samples of erythema migrans patients with clinical findings. PLoS One. 2015;10:e0136600. https://doi.org/10.1371/journal.pone.0136600 Provides evidence that Borrelia burden in lesional skin is correlated with increased treatment resistance and increased size of lesions and increased likelihood of central clearing. CrossRefPubMedPubMedCentral

52.

•• Mazori DR, Orme CM, Mir A, Meehan SA, Neimann AL. Vesicular erythema migrans: an atypical and easily misdiagnosed form of Lyme disease. Dermatol Online J. 2015;21. Provides an example of an atypical vesicular presentation of erythema migrans as seen in Lyme disease, and serves as a reminder to consider Lyme disease in atypical appearing cases in high-risk populations.

53.

•• Paul S, Song PI, Ogbechie OA, Sugai DY, Morley KW, Schalock PC, et al. Vesiculobullous and hemorrhagic erythema migrans: uncommon variants of a common disease. Int J Dermatol. 2016;55:e79–82. https://doi.org/10.1111/ijd.12927 Describes atypical variants of erythema migrans, including hemorrhagic and vesiculobullous erythema migrans. CrossRefPubMed

54.

Gore M, Winters ME. Erythema gyratum repens: a rare paraneoplastic rash. West J Emerg Med. 2011;12:556–8. https://doi.org/10.5811/westjem.2010.11.2090.CrossRefPubMedPubMedCentral

55.

Rongioletti F, Fausti V, Parodi A. Erythema gyratum repens is not an obligate paraneoplastic disease: a systematic review of the literature and personal experience. J Eur Acad Dermatol Venereol. 2014;28:112–5. https://doi.org/10.1111/j.1468-3083.2012.04663.x.CrossRefPubMed

56.

Kleyn CE, Lai-Cheong JE, Bell HK. Cutaneous manifestations of internal malignancy: diagnosis and management. Am J Clin Dermatol. 2006;7:71–84.CrossRef

57.

Kim KJ, Chang SE, Choi JH, Sung KJ, Moon KC, Koh JK. Clinicopathologic analysis of 66 cases of erythema annulare centrifugum. J Dermatol. 2002;29:61–7.CrossRef

58.

Weyers W, Diaz-Cascajo C, Weyers I. Erythema annulare centrifugum: results of a clinicopathologic study of 73 patients. Am J Dermatopathol. 2003;25:451–62.CrossRef

59.

•• Wu W-M, Chuang F-C, Lin S-H. Erythromycin as a safe and effective treatment option for erythema annulare centrifugum. Indian J Dermatol. 2015;60:519. https://doi.org/10.4103/0019-5154.159633 A recent report with new evidence for erythromycin as a viable and efficient treatment option of erythema annulare centrifugum. CrossRefPubMedPubMedCentral

60.

•• Martinez-Saguer I, Farkas H. Erythema marginatum as an early symptom of hereditary angioedema: case report of 2 newborns. Pediatrics. 2016;137:e20152411–1. https://doi.org/10.1542/peds.2015-2411 Calls attention to the need to evlauate for genetic underpinnings of erythema marginatum in infants, such as heriditary angioedema. CrossRef

61.

• Kadavath S, Efthimiou P. Adult-onset Still’s disease—pathogenesis, clinical manifestations, and new treatment options. Ann Med. 2015;47:6–14. https://doi.org/10.3109/07853890.2014.971052 Outlines clinical and laboratory findings in adult-onset Still’s disease that may help in the diagnosis of figurate erythemas. CrossRefPubMed

Title: Erythroderma and Figurate Erythemas
Authors: Emily Coleman
Lauren L. Levy
Publication date: 01-12-2018
Publisher: Springer US
Published in: Current Dermatology Reports / Issue 4/2018
Electronic ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-018-0236-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Erythroderma and Figurate Erythemas

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2018

Wound Healing with Botanicals: a Review and Future Perspectives

Healing Chronic Wounds: Current Challenges and Potential Solutions

Updates on Immunotherapy for the Treatment of Skin Cancer

Current Psoriasis Efficacy Outcome Measures in Clinical Trials

The Skin Microbiome in Atopic Dermatitis—a Potential Treatment Target?

Immunology of Wound Healing